Dr. Vania Mardirossian

DMD | Dentist



  
  5209 N Oracle Rd, Tucson
  Arizona, 85704-3707

  520-293-9277    520-393-3723 Maps & Directions
Dr. Vania Mardirossian is a Tucson, Arizona based Dentist who is specialized in Dentistry. She may accept the Medicare-approved amount. Patients may be billed for more than the Medicare deductible and coinsurance. Her current practice location is 5209 N Oracle Rd, Tucson. Patients can reach her at 520-293-9277.
Dr. Vania Mardirossian is the primary dental care provider for patients of all ages. She is responsible for the diagnosis, treatment, management and overall coordination of services related to patients' oral health needs.
Complete Profile:
Dr. Vania Mardirossian speciality, credentials, practice address, contact phone number and fax are as below. Patients can directly walk in or can call on the below given phone number for appointment.
Name: Dr. Vania Mardirossian
Specialization: Dentist
Gender:Female
Credentials: DMD
Accepts Medicare Assignment:May Accept
Practice Address:5209 N Oracle Rd, Tucson,
Arizona, 85704-3707
Phone:520-293-9277
Fax:520-393-3723
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS). NPI details are as mentioned below.
PAC ID: 9335434414
Enrollment ID: I20160829001761
NPI Number: 1790138683
NPI Enumeration Date: 15 Jul, 2016
NPI Last Update On: 15 Jul, 2016

Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address: 5209 N Oracle Rd,
Tucson, Arizona
Zip: 85704-3707
Phone Number: 520-293-9277
Fax Number: 520-393-3723
Patients can reach Dr. Vania Mardirossian at 5209 N Oracle Rd, Tucson, Arizona or can call to book an appointment on 520-293-9277. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.

Comments/ Reviews: